Latest in Cardiology from ACC.org

• SUMMIT Analysis: Does BMI and Central Adiposity Affect Tirzepatide Outcomes For HFpEF?
  Although tirzepatide showed no heterogeneity in primary cardiovascular outcomes for differing baseline BMI or central adiposity, individuals with heart failure (HF) with preserved ejection fraction (HFpEF) with higher BMI at baseline showed greater improvement in six-minute walking distance...
• 18F Flurpiridaz PET MPI: New Horizons in Cardiac Imaging
  Fluorine-18 (18F) flurpiridaz is a radiotracer for positron emission tomography (PET) myocardial perfusion imaging (MPI) newly approved by the Food and Drug Administration (FDA), offering several advantages due to its favorable physical properties.
• Proposed 2026 Medicare Physician Fee Schedule: An ACC Advocacy Deep Dive
  The Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Physician Fee Schedule (PFS) proposed rule, updating the PFS conversion factor from $32.3465 to $33.5875 for qualifying alternative payment model (APM) participants and $33.4209 for non-qualifying APM participants...
• Increased Use of Radial Access For PCI in the US, Lower Complication Rates | NCDR Study
  PCI with radial access site is associated with lower rates of in-hospital mortality, major access site bleeding and other major vascular complications vs. femoral access site and has increased in use in the U.S. over the past decade, overtaking femoral access site...
• Peripheral Interventions: Drug-Coated Balloon Endovascular Therapy and Transcatheter Arterialization of Deep Veins
  Drug-coated ballon (DCB) endovascular therapy was found to be a reasonable treatment for femoropopliteal lesions in patients on hemodialysis, according to research published July 14 in JACC: Cardiovascular Interventions.